Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein

Stukova, Marina; Sereinig, Sabine; Zabolotnyh, Natalya; Ferko, Boris; Kittel, Christian; Romanova, Julia; Виноградова, Т И; Katinger, Hermann; Киселев, О. И.; Egorov, Andrej

doi:10.1016/j.tube.2006.01.010

Cited by 46 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These vaccine candidates are capable of inducing the enhanced Th1 systemic and the local mucosal immune response at the infection entry. The current research data prove that the vector technology based on the modification of the NS segment of influenza virus enables the generation of highly immunogenic recombinant virus strains that express the foreign sequences from the NS1 reading frame [90][91][92][93][94][95][96]. Clinical trials showed that viruses with the modified NS gene are safe and highly immunogenic [97].…”

Section: Resultsmentioning

confidence: 75%

The challenges of creating a universal influenza vaccine

Egorov¹

2016

Microbiology Independent Research Journal (MIR Journal)

View full text Add to dashboard Cite

The lack of population immunity to the periodically emerging pandemic influenza strains makes influenza infection especially dangerous. The fragmented nature of the influenza virus genome contributes to the formation of influenza virus reassortants containing genomic fragments from different strains. This mechanism is the main reason for the natural influenza virus antigenic diversity as well as for the occurrence of influenza pandemics. Vaccination is the best measure to prevent the spread of influenza infection, but the efficacy of existing vaccines is not sufficient, especially for the elderly and small children. Specific immunity, developed after disease or immunization, poorly protects against infection by influenza viruses of another subtype. In this regard, there is an urgent need for a more effective universal influenza vaccine that provides a long-lasting broad cross-protective immunity, and is able to protect against influenza A and B viruses of all known subtypes. The basic approaches to as well as challenges of creating such a vaccine are discussed in this review.

show abstract

Section: Resultsmentioning

confidence: 75%

The challenges of creating a universal influenza vaccine

Egorov¹

2016

Microbiology Independent Research Journal (MIR Journal)

View full text Add to dashboard Cite

show abstract

“…116 Recently, our group utilized a model of recombinant influenza expressing a single, immunodominant LACK 158-173 CD4 + T-cell peptide, and demonstrated that a prime/boost approach resulted in considerable protection against Leishmania in a mouse model and was associated with increased IFNγ production by CD4 + T cells (Kedzierska et al manuscript submitted). Influenza viruses are attractive candidates as vaccine vectors, with the approach being tried so far for HIV, 117 tuberculosis, 118 malaria 119 and cancer. 120 These results point to the value of recombinant influenza vector for Leishmania vaccination.…”

Section: Discussionmentioning

confidence: 99%

Leishmaniasis

Kędzierski¹

2011

Human Vaccines

View full text Add to dashboard Cite

“…This construct provides potent protection against challenge with tuberculosis to mice and guinea pigs when administered via the intranasal route. Moreover, protection by this influenza virus is similar to that induced by the Mycobacterium bovis Bacillus Calmette-Guérin strain (BCG), and has a synergistic effect when used with chemotherapy 56 , 57 …”

Section: Replication-competent Influenza Virus-vectored Vaccinesmentioning

confidence: 97%

Engineering influenza viral vectors

Li¹,

Arévalo²,

Zeng

2013

Bioengineered

View full text Add to dashboard Cite

The influenza virus is a respiratory pathogen with a negative-sense, segmented RNA genome. Construction of recombinant influenza viruses in the laboratory was reported starting in the 1980s. Within a short period of time, pioneer researchers had devised methods that made it possible to construct influenza viral vectors from cDNA plasmid systems. Herein, we discuss the evolution of influenza virus reverse genetics, from helper virus-dependent systems, to helper virus-independent 17-plasmid systems, and all the way to 3- and 1- plasmid systems. Successes in the modification of different gene segments for various applications, including vaccine and gene therapies are highlighted.

show abstract

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein

Cited by 46 publications

References 35 publications

The challenges of creating a universal influenza vaccine

The challenges of creating a universal influenza vaccine

Leishmaniasis

Engineering influenza viral vectors

Contact Info

Product

Resources

About